Variables significantly associated with ScGVHD in univariate analysis
| . | Nonsclerotic GVHD . | ScGVHD . | P . |
|---|---|---|---|
| Patient, transplantation, and cGVHD characteristics | |||
| Karnofsky status | 82.25 (1.40) | 77.45 (1.20) | .003 |
| Number of previous therapies | 2.83 (0.18) | 4.72 (0.18) | < .0001 |
| Days from transplantation to cGVHD diagnosis | 245.2 (25.60) | 350.94 (34.45) | < .0001 |
| Days from cGVHD diagnosis to enrollment | 953.48 (136.83) | 1293.28 (113.37) | < .0001 |
| Total body irradiation | 25/97 (25.77%) | 50/107 (46.73%) | .0023 |
| High intensity of immunosuppression* | 30/97 (30.93%) | 49/108 (45.4%) | .021 |
| Laboratory parameters | |||
| Platelet count, 1000/μL | 224.86 (10.06) | 293.47 (11.37) | < .0001 |
| CRP, mg/dL | 1.16 (0.22) | 1.23 (0.92) | .0012 |
| C3 complement, mg/dL | 120.93 (2.62) | 144.21 (2.97) | < .0001 |
| C4 complement, mg/dL | 24.48 (0.82) | 29.45 (1.00) | < .0001 |
| Total complement, mg/dL | 123.51 (3.21) | 135.43 (3.34) | .017 |
| IgM, mg/dL | 87.6 (7.35) | 71.68 (7.60) | .024 |
| Cardiolipin IgM, mg/dL* | 8/96 (8.33%) | 1/101 (0.99%) | .0019 |
| Percent predicted FVC | 84.73 (1.99) | 74.58 (2.10) | .013 |
| Functional measures | |||
| Severe NIH Joint/Fascia score* | 0/88 | 20/106 (18.87%) | < .0001 |
| Severe NIH global score | 37/88 (42.05%) | 86/106 (81.13%) | < .0001 |
| ROM | 74.72 (2.89) | 48.02 (3.03) | < .0001 |
| Grip strength | 73.41 (3.03) | 56.77 (2.35) | < .0001 |
| Patient-reported measures | |||
| Skin color change: quite a bit or extreme* | 15/79 (18.99%) | 28/88 (31.82%) | .0074 |
| Skin thickness: quite a bit or extreme* | 6/79 (7.59%) | 46/87 (52.87%) | .0001 |
| Sores on skin: quite a bit or extreme * | 9/77 (11.69%) | 16/88 (18.18%) | .0239 |
| Skin itching: quite a bit or extreme* | 11/79 (13.92%) | 29/88 (32.95%) | .0112 |
| Joint stiffness: quite a bit or extreme * | 7/79 (8.86%) | 41/88 (46.59%) | .0001 |
| . | Nonsclerotic GVHD . | ScGVHD . | P . |
|---|---|---|---|
| Patient, transplantation, and cGVHD characteristics | |||
| Karnofsky status | 82.25 (1.40) | 77.45 (1.20) | .003 |
| Number of previous therapies | 2.83 (0.18) | 4.72 (0.18) | < .0001 |
| Days from transplantation to cGVHD diagnosis | 245.2 (25.60) | 350.94 (34.45) | < .0001 |
| Days from cGVHD diagnosis to enrollment | 953.48 (136.83) | 1293.28 (113.37) | < .0001 |
| Total body irradiation | 25/97 (25.77%) | 50/107 (46.73%) | .0023 |
| High intensity of immunosuppression* | 30/97 (30.93%) | 49/108 (45.4%) | .021 |
| Laboratory parameters | |||
| Platelet count, 1000/μL | 224.86 (10.06) | 293.47 (11.37) | < .0001 |
| CRP, mg/dL | 1.16 (0.22) | 1.23 (0.92) | .0012 |
| C3 complement, mg/dL | 120.93 (2.62) | 144.21 (2.97) | < .0001 |
| C4 complement, mg/dL | 24.48 (0.82) | 29.45 (1.00) | < .0001 |
| Total complement, mg/dL | 123.51 (3.21) | 135.43 (3.34) | .017 |
| IgM, mg/dL | 87.6 (7.35) | 71.68 (7.60) | .024 |
| Cardiolipin IgM, mg/dL* | 8/96 (8.33%) | 1/101 (0.99%) | .0019 |
| Percent predicted FVC | 84.73 (1.99) | 74.58 (2.10) | .013 |
| Functional measures | |||
| Severe NIH Joint/Fascia score* | 0/88 | 20/106 (18.87%) | < .0001 |
| Severe NIH global score | 37/88 (42.05%) | 86/106 (81.13%) | < .0001 |
| ROM | 74.72 (2.89) | 48.02 (3.03) | < .0001 |
| Grip strength | 73.41 (3.03) | 56.77 (2.35) | < .0001 |
| Patient-reported measures | |||
| Skin color change: quite a bit or extreme* | 15/79 (18.99%) | 28/88 (31.82%) | .0074 |
| Skin thickness: quite a bit or extreme* | 6/79 (7.59%) | 46/87 (52.87%) | .0001 |
| Sores on skin: quite a bit or extreme * | 9/77 (11.69%) | 16/88 (18.18%) | .0239 |
| Skin itching: quite a bit or extreme* | 11/79 (13.92%) | 29/88 (32.95%) | .0112 |
| Joint stiffness: quite a bit or extreme * | 7/79 (8.86%) | 41/88 (46.59%) | .0001 |
For each of the groups, fibrotic and nonfibrotic, continuous variables are shown as means and SE. Categorical variables are shown as proportions with percentages for each group.
cGVHD indicates chronic GVHD; CRP, C-reactive protein; FVC, forced vital capacity; NIH, National Institutes of Health; ROM, range of motion; and ScGVHD, sclerotic-type chronic GVHD.
Ordered categorical variable, presented as fraction for simplicity. Comparisons were performed with the use of the Cochran-Armitage test for trend.